SCHEMBL22399622

SCHEMBL22399622

NC(=O)O[C@H]1C[C@@H](CO)N(Cc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC11 Q96DB2 2/20 0.43
▸ SIGMAR1 Q99720 1/20 0.42
▸ CHRM2 P08172 1/20 0.41
▸ CHRM4 P08173 1/20 0.41
▸ CHRM5 P08912 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ GBA1 P04062 1/20 0.40
▸ KCNH2 Q12809 3/20 0.39
▸ OPRK1 P41145 2/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA4 P22748 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ SPHK2 Q9NRA0 1/20 0.38
▸ SPHK1 Q9NYA1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28356152 0.90 BDKRB2 (0.42) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL14012809 0.81 SIGMAR1 (0.51) HDAC11SIGMAR1GBA1MAPTSPHK2
SCHEMBL14012805 0.81 SIGMAR1 (0.51) HDAC11SIGMAR1GBA1MAPTSPHK2
SCHEMBL15593209 0.81 SIGMAR1 (0.51) HDAC11SIGMAR1GBA1MAPTSPHK2
SCHEMBL29105856 0.80 CTSL (0.49) HDAC11SIGMAR1GBA1MAPTSPHK2
SCHEMBL28352623 0.80 BTK (0.42) HDAC11SIGMAR1CHRM3GBA1CA1
SCHEMBL16399825 0.78 SIGMAR1 (0.46) HDAC11SIGMAR1GBA1MAPT
SCHEMBL30843731 0.76 MAPT (0.48) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL7309438 0.76 MAPT (0.45) HDAC11SIGMAR1GBA1MAPTSPHK2
SCHEMBL7308251 0.76 MAPT (0.45) HDAC11SIGMAR1GBA1MAPTSPHK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
CN-110770224-A Indole derivatives as efflux pump inhibitors 罗格斯新泽西州立大学 2020-02-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 HDAC11 780/4885SIGMAR1 1660/4885CHRM2 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback